Based on the strong anti-tumor efficacy of RORγ antagonists XY018, XY101, and SR2211 in PCa cell line-derived xenograft models, we proposed that targeting RORγ can be an efficacious strategy to treat advanced CRPCs [18,22]. Here, RORC is linked to neoplasm.